New strategies to improve clinical outcomes for diabetic kidney disease

Background Diabetic kidney disease (DKD), the most common cause of kidney failure and end-stage kidney disease worldwide, will develop in almost half of all people with type 2 diabetes. With the incidence of type 2 diabetes continuing to increase, early detection and management of DKD is of great cl...

Full description

Saved in:
Bibliographic Details
Published inBMC medicine Vol. 20; no. 1; pp. 1 - 15
Main Authors Forst, Thomas, Mathieu, Chantal, Giorgino, Francesco, Wheeler, David C., Papanas, Nikolaos, Schmieder, Roland E., Halabi, Atef, Schnell, Oliver, Streckbein, Marina, Tuttle, Katherine R.
Format Journal Article
LanguageEnglish
Published London BioMed Central Ltd 10.10.2022
BioMed Central
BMC
Subjects
Blood pressure
Cardiovascular disease
Care and treatment
Cholesterol
Clinical outcomes
Clinical trials
Creatinine
Diabetes
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Diabetic kidney disease
Diabetic nephropathies
Diabetic nephropathy
Diagnosis
End-stage renal disease
Glomerular filtration rate
Glucose
Health services
Hemodialysis
Hypertension
Kidney diseases
Kidney protective agents
Kidneys
Mortality
Pathophysiology
Reagents
Renal failure
Review
Risk factors
Transplants & implants
Type 2 diabetes
United States
Online AccessGet full text

Cover

Abstract Background Diabetic kidney disease (DKD), the most common cause of kidney failure and end-stage kidney disease worldwide, will develop in almost half of all people with type 2 diabetes. With the incidence of type 2 diabetes continuing to increase, early detection and management of DKD is of great clinical importance. Main body This review provides a comprehensive clinical update for DKD in people with type 2 diabetes, with a special focus on new treatment modalities. The traditional strategies for prevention and treatment of DKD, i.e., glycemic control and blood pressure management, have only modest effects on minimizing glomerular filtration rate decline or progression to end-stage kidney disease. While cardiovascular outcome trials of SGLT-2i show a positive effect of SGLT-2i on several kidney disease-related endpoints, the effect of GLP-1 RA on kidney-disease endpoints other than reduced albuminuria remain to be established. Non-steroidal mineralocorticoid receptor antagonists also evoke cardiovascular and kidney protective effects. Conclusion With these new agents and the promise of additional agents under clinical development, clinicians will be more able to personalize treatment of DKD in patients with type 2 diabetes. Keywords: Type 2 diabetes, Diabetic kidney disease, Kidney protective agents
AbstractList Background Diabetic kidney disease (DKD), the most common cause of kidney failure and end-stage kidney disease worldwide, will develop in almost half of all people with type 2 diabetes. With the incidence of type 2 diabetes continuing to increase, early detection and management of DKD is of great clinical importance. Main body This review provides a comprehensive clinical update for DKD in people with type 2 diabetes, with a special focus on new treatment modalities. The traditional strategies for prevention and treatment of DKD, i.e., glycemic control and blood pressure management, have only modest effects on minimizing glomerular filtration rate decline or progression to end-stage kidney disease. While cardiovascular outcome trials of SGLT-2i show a positive effect of SGLT-2i on several kidney disease-related endpoints, the effect of GLP-1 RA on kidney-disease endpoints other than reduced albuminuria remain to be established. Non-steroidal mineralocorticoid receptor antagonists also evoke cardiovascular and kidney protective effects. Conclusion With these new agents and the promise of additional agents under clinical development, clinicians will be more able to personalize treatment of DKD in patients with type 2 diabetes.
Background Diabetic kidney disease (DKD), the most common cause of kidney failure and end-stage kidney disease worldwide, will develop in almost half of all people with type 2 diabetes. With the incidence of type 2 diabetes continuing to increase, early detection and management of DKD is of great clinical importance. Main body This review provides a comprehensive clinical update for DKD in people with type 2 diabetes, with a special focus on new treatment modalities. The traditional strategies for prevention and treatment of DKD, i.e., glycemic control and blood pressure management, have only modest effects on minimizing glomerular filtration rate decline or progression to end-stage kidney disease. While cardiovascular outcome trials of SGLT-2i show a positive effect of SGLT-2i on several kidney disease-related endpoints, the effect of GLP-1 RA on kidney-disease endpoints other than reduced albuminuria remain to be established. Non-steroidal mineralocorticoid receptor antagonists also evoke cardiovascular and kidney protective effects. Conclusion With these new agents and the promise of additional agents under clinical development, clinicians will be more able to personalize treatment of DKD in patients with type 2 diabetes. Keywords: Type 2 diabetes, Diabetic kidney disease, Kidney protective agents
Diabetic kidney disease (DKD), the most common cause of kidney failure and end-stage kidney disease worldwide, will develop in almost half of all people with type 2 diabetes. With the incidence of type 2 diabetes continuing to increase, early detection and management of DKD is of great clinical importance. With these new agents and the promise of additional agents under clinical development, clinicians will be more able to personalize treatment of DKD in patients with type 2 diabetes.
Abstract Background Diabetic kidney disease (DKD), the most common cause of kidney failure and end-stage kidney disease worldwide, will develop in almost half of all people with type 2 diabetes. With the incidence of type 2 diabetes continuing to increase, early detection and management of DKD is of great clinical importance. Main body This review provides a comprehensive clinical update for DKD in people with type 2 diabetes, with a special focus on new treatment modalities. The traditional strategies for prevention and treatment of DKD, i.e., glycemic control and blood pressure management, have only modest effects on minimizing glomerular filtration rate decline or progression to end-stage kidney disease. While cardiovascular outcome trials of SGLT-2i show a positive effect of SGLT-2i on several kidney disease-related endpoints, the effect of GLP-1 RA on kidney-disease endpoints other than reduced albuminuria remain to be established. Non-steroidal mineralocorticoid receptor antagonists also evoke cardiovascular and kidney protective effects. Conclusion With these new agents and the promise of additional agents under clinical development, clinicians will be more able to personalize treatment of DKD in patients with type 2 diabetes.
Diabetic kidney disease (DKD), the most common cause of kidney failure and end-stage kidney disease worldwide, will develop in almost half of all people with type 2 diabetes. With the incidence of type 2 diabetes continuing to increase, early detection and management of DKD is of great clinical importance.BACKGROUNDDiabetic kidney disease (DKD), the most common cause of kidney failure and end-stage kidney disease worldwide, will develop in almost half of all people with type 2 diabetes. With the incidence of type 2 diabetes continuing to increase, early detection and management of DKD is of great clinical importance.This review provides a comprehensive clinical update for DKD in people with type 2 diabetes, with a special focus on new treatment modalities. The traditional strategies for prevention and treatment of DKD, i.e., glycemic control and blood pressure management, have only modest effects on minimizing glomerular filtration rate decline or progression to end-stage kidney disease. While cardiovascular outcome trials of SGLT-2i show a positive effect of SGLT-2i on several kidney disease-related endpoints, the effect of GLP-1 RA on kidney-disease endpoints other than reduced albuminuria remain to be established. Non-steroidal mineralocorticoid receptor antagonists also evoke cardiovascular and kidney protective effects.MAIN BODYThis review provides a comprehensive clinical update for DKD in people with type 2 diabetes, with a special focus on new treatment modalities. The traditional strategies for prevention and treatment of DKD, i.e., glycemic control and blood pressure management, have only modest effects on minimizing glomerular filtration rate decline or progression to end-stage kidney disease. While cardiovascular outcome trials of SGLT-2i show a positive effect of SGLT-2i on several kidney disease-related endpoints, the effect of GLP-1 RA on kidney-disease endpoints other than reduced albuminuria remain to be established. Non-steroidal mineralocorticoid receptor antagonists also evoke cardiovascular and kidney protective effects.With these new agents and the promise of additional agents under clinical development, clinicians will be more able to personalize treatment of DKD in patients with type 2 diabetes.CONCLUSIONWith these new agents and the promise of additional agents under clinical development, clinicians will be more able to personalize treatment of DKD in patients with type 2 diabetes.
ArticleNumber 337
Audience Academic
Author Forst, Thomas
Schnell, Oliver
Streckbein, Marina
Tuttle, Katherine R.
Mathieu, Chantal
Giorgino, Francesco
Schmieder, Roland E.
Papanas, Nikolaos
Halabi, Atef
Wheeler, David C.
Author_xml – sequence: 1
  givenname: Thomas
  surname: Forst
  fullname: Forst, Thomas
– sequence: 2
  givenname: Chantal
  surname: Mathieu
  fullname: Mathieu, Chantal
– sequence: 3
  givenname: Francesco
  surname: Giorgino
  fullname: Giorgino, Francesco
– sequence: 4
  givenname: David C.
  surname: Wheeler
  fullname: Wheeler, David C.
– sequence: 5
  givenname: Nikolaos
  surname: Papanas
  fullname: Papanas, Nikolaos
– sequence: 6
  givenname: Roland E.
  surname: Schmieder
  fullname: Schmieder, Roland E.
– sequence: 7
  givenname: Atef
  surname: Halabi
  fullname: Halabi, Atef
– sequence: 8
  givenname: Oliver
  surname: Schnell
  fullname: Schnell, Oliver
– sequence: 9
  givenname: Marina
  surname: Streckbein
  fullname: Streckbein, Marina
– sequence: 10
  givenname: Katherine R.
  surname: Tuttle
  fullname: Tuttle, Katherine R.
BookMark eNp9kltr3DAQhU1Jobn0D_TJUCh9cWqNbvZLIYQ2DYTmpX0Wsjza1da2tpKdkn_f2WxKs6EUYyxL3znSjM5JcTTFCYviDavPGWvUh8ygZaqqAeiVvK3gRXHMtGCVrpk8ejJ-VZzkvKmJ0locF1df8VeZ52RnXAXM5RzLMG5TvMPSDWEKzg5lXGYXR1r0MZV9sB3OwZU_Qj_hPf1ntBnPipfeDhlfP35Pi--fP327_FLd3F5dX17cVE5xPVdge1Ci00oj19x3Te9FL2opoZPAARzvrAbuPWtFD61rNPrOqV5KjrUCzU-L671vH-3GbFMYbbo30QbzMBHTythExxvQKKihRgXWCyYQ6sZRxdC0rdCMoe7I6-Pea7t0I_YOJ-rDcGB6uDKFtVnFO9NK0fBGkcH7R4MUfy6YZzOG7HAY7IRxyQaoFNFoxTihb5-hm7ikiVq1o2TL6X70X2plqYAw-Uj7up2pudDANAgpJFHn_6Do6XEMjoLhA80fCN49EazRDvM6x2GZQ5zyIdjsQZdizgm9cWG2O4x2CINhtdnFzezjZihu5iFuBkgKz6R_-vgf0W-iI9Z8
CitedBy_id crossref_primary_10_1007_s13659_024_00446_y
crossref_primary_10_2174_0929867331666230914091944
crossref_primary_10_4103_bbrj_bbrj_46_25
crossref_primary_10_1007_s11655_024_3919_x
crossref_primary_10_1016_j_lfs_2024_122801
crossref_primary_10_12968_bjon_2023_32_18_874
crossref_primary_10_1016_j_joim_2024_03_010
crossref_primary_10_3389_fmed_2024_1471642
crossref_primary_10_3389_fphar_2024_1349022
crossref_primary_10_1016_j_jep_2024_118650
crossref_primary_10_1016_j_jep_2024_118179
crossref_primary_10_14814_phy2_70058
crossref_primary_10_3390_nu15245039
crossref_primary_10_3389_fendo_2022_1071465
crossref_primary_10_1177_08971900241262381
crossref_primary_10_2147_CLEP_S463363
crossref_primary_10_1172_JCI170341
crossref_primary_10_1016_j_cellsig_2023_110883
crossref_primary_10_1016_j_ejps_2025_107045
crossref_primary_10_1681_ASN_0000000000000438
crossref_primary_10_3389_fmed_2024_1376115
crossref_primary_10_1016_j_trsl_2023_10_007
crossref_primary_10_1007_s12272_024_01521_1
crossref_primary_10_62347_MCEE4840
crossref_primary_10_1080_17512433_2024_2421872
crossref_primary_10_1111_dom_15860
crossref_primary_10_3389_fendo_2025_1513008
crossref_primary_10_1186_s12882_024_03869_4
crossref_primary_10_2147_RMHP_S354549
crossref_primary_10_1136_bmjdrc_2023_003422
crossref_primary_10_1248_bpb_b23_00390
crossref_primary_10_3389_fendo_2023_1142276
crossref_primary_10_3390_nu15020377
crossref_primary_10_3892_ijmm_2024_5428
crossref_primary_10_4239_wjd_v14_i10_1450
crossref_primary_10_1016_j_clim_2024_110379
crossref_primary_10_2147_DDDT_S411211
crossref_primary_10_1038_s41598_023_42665_2
crossref_primary_10_3389_fmed_2023_1143028
crossref_primary_10_1080_0886022X_2024_2381597
crossref_primary_10_1136_bmjdrc_2024_004282
crossref_primary_10_12998_wjcc_v12_i3_538
crossref_primary_10_1016_j_jdiacomp_2023_108478
crossref_primary_10_1016_j_ejmech_2024_117134
crossref_primary_10_1016_j_semnephrol_2024_151519
crossref_primary_10_1016_j_phymed_2023_154959
crossref_primary_10_1007_s10787_024_01452_9
crossref_primary_10_3389_fmicb_2023_1207132
crossref_primary_10_21070_medicra_v7i2_1751
Cites_doi 10.1056/NEJMoa1509225
10.1056/NEJMe2114918
10.1053/j.ackd.2017.12.002
10.1016/j.bbadis.2020.165796
10.1016/j.kint.2020.06.019
10.1056/NEJMoa1515920
10.1016/j.molmet.2019.10.005
10.1016/S0140-6736(10)60576-4
10.1373/clinchem.2016.264325
10.1093/ndt/gfn379
10.1001/jama.2010.39
10.1038/nrneph.2015.173
10.1056/NEJMoa0808431
10.1152/ajprenal.00314.2016
10.1681/ASN.2006080872
10.1056/NEJMoa2004967
10.1056/NEJMra1808786
10.1056/NEJMoa2022190
10.1136/bmj.317.7160.703
10.1038/s41581-020-00367-2
10.1161/HYPERTENSIONAHA.117.10360
10.1186/s40001-021-00612-9
10.1053/j.ajkd.2021.08.003
10.1016/j.metabol.2021.154937
10.2337/dc21-S010
10.1056/NEJMoa2110956
10.1001/jamanetworkopen.2021.48940
10.1056/NEJMoa2102953
10.2215/CJN.11111016
10.1136/bmj.k1497
10.1159/000333249
10.1056/NEJMoa1607141
10.1016/j.kint.2020.11.003
10.2215/CJN.11491116
10.1056/NEJMoa1616011
10.1056/NEJMoa1800256
10.1001/jama.2016.10924
10.1093/eurheartj/ehaa736
10.1097/MED.0000000000000311
10.1681/ASN.2010010010
10.3390/jcm9040947
10.1056/NEJMoa1611925
10.1016/S0140-6736(18)32261-X
10.1331/JAPhA.2009.09078
10.2174/1568026620666191224141617
10.1056/NEJMoa2025845
10.1093/eurheartj/ehab777
10.1056/NEJMoa2108269
10.1097/HJH.0b013e3283495cd6
10.1056/NEJMoa1811744
10.1056/NEJMoa2024816
10.1016/S0140-6736(10)60674-5
10.1186/1475-2840-13-102
10.1038/kisup.2012.73
10.2337/dc20-S006
10.1111/jdi.13355
10.1016/j.kint.2016.05.002
10.1016/S0140-6736(98)07019-6
10.1016/j.semnephrol.2018.02.002
10.1038/s41574-019-0242-2
10.1016/j.beem.2009.03.004
10.1016/j.kint.2019.02.030
10.2165/00003495-200363130-00004
10.1056/NEJMoa1812389
10.1038/kisup.2013.27
10.2337/dc20-S011
10.1016/S2213-8587(18)30104-9
10.1016/S0140-6736(19)31150-X
10.1097/MNH.0000000000000557
10.1186/s12933-019-0942-x
ContentType Journal Article
Copyright COPYRIGHT 2022 BioMed Central Ltd.
2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2022. The Author(s).
The Author(s) 2022
Copyright_xml – notice: COPYRIGHT 2022 BioMed Central Ltd.
– notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2022. The Author(s).
– notice: The Author(s) 2022
DBID AAYXX
CITATION
3V.
7QL
7U9
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
C1K
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
M7N
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12916-022-02539-2
DatabaseName CrossRef
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals - May need to register for free articles
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Virology and AIDS Abstracts
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database




MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1741-7015
EndPage 15
ExternalDocumentID oai_doaj_org_article_62020e62af414e208c77428994711e7b
PMC9548386
A721724545
10_1186_s12916_022_02539_2
GeographicLocations United States
GeographicLocations_xml – name: United States
GrantInformation_xml – fundername: ;
GroupedDBID ---
0R~
23N
2WC
4.4
53G
5GY
5VS
6J9
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
IHW
INH
INR
ITC
KQ8
M1P
M48
MK0
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
WOQ
WOW
XSB
PMFND
3V.
7QL
7U9
7XB
8FK
AZQEC
C1K
DWQXO
H94
K9.
M7N
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c637t-2ad264b767e373fb8df4d40552b52322c3ba723ff194d29c87efbc6d553e06273
IEDL.DBID M48
ISSN 1741-7015
IngestDate Wed Aug 27 00:46:42 EDT 2025
Thu Aug 21 18:39:46 EDT 2025
Tue Aug 05 11:14:13 EDT 2025
Sat Jul 26 02:23:18 EDT 2025
Tue Jun 17 21:34:44 EDT 2025
Tue Jun 10 20:41:13 EDT 2025
Thu May 22 21:22:34 EDT 2025
Thu Apr 24 23:00:52 EDT 2025
Tue Jul 01 02:51:32 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c637t-2ad264b767e373fb8df4d40552b52322c3ba723ff194d29c87efbc6d553e06273
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
OpenAccessLink https://www.proquest.com/docview/2725937417?pq-origsite=%requestingapplication%
PQID 2725937417
PQPubID 42775
PageCount 15
ParticipantIDs doaj_primary_oai_doaj_org_article_62020e62af414e208c77428994711e7b
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9548386
proquest_miscellaneous_2723487613
proquest_journals_2725937417
gale_infotracmisc_A721724545
gale_infotracacademiconefile_A721724545
gale_healthsolutions_A721724545
crossref_citationtrail_10_1186_s12916_022_02539_2
crossref_primary_10_1186_s12916_022_02539_2
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-10-10
PublicationDateYYYYMMDD 2022-10-10
PublicationDate_xml – month: 10
  year: 2022
  text: 2022-10-10
  day: 10
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle BMC medicine
PublicationYear 2022
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References T Benzing (2539_CR15) 2021; 384
W Duckworth (2539_CR69) 2009; 360
M Afkarian (2539_CR59) 2016; 316
MA Pfeffer (2539_CR58) 2015; 373
SD Wiviott (2539_CR47) 2018; 380
B Neal (2539_CR46) 2017; 377
M Foretz (2539_CR38) 2019; 15
C Delgado (2539_CR24) 2022; 79
L Deng (2539_CR18) 2021; 26
U.S. National Library of Medicine (2539_CR66) 2022
SP Marso (2539_CR53) 2016; 375
NA Thornberry (2539_CR61) 2009; 23
RZ Alicic (2539_CR11) 2017; 12
MC Thomas (2539_CR4) 2016; 12
H Fu (2539_CR6) 2019; 30
RZ Alicic (2539_CR10) 2018; 25
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group (2539_CR27) 2020; 98
UK Prospective Diabetes Study Group (2539_CR37) 1998; 317
GL Bakris (2539_CR67) 2020; 383
J Grune (2539_CR73) 2018; 71
BA Perkins (2539_CR23) 2007; 18
I Caruso (2539_CR71) 2022; 127
O Gheith (2539_CR5) 2016; 5
U.S. National Library of Medicine (2539_CR65) 2022
G Penno (2539_CR16) 2011; 29
KR Tuttle (2539_CR56) 2018; 6
R Agarwal (2539_CR74) 2021; 42
2539_CR3
LE Clegg (2539_CR54) 2019; 18
CM Wyatt (2539_CR64) 2016; 90
H Li (2539_CR7) 2021; 3
2539_CR1
M Frimodt-Møller (2539_CR75) 2020; 29
HC Gerstein (2539_CR60) 2021; 385
LA Inker (2539_CR26) 2021; 385
American Diabetes Association (2539_CR32) 2020; 43
AF Hernandez (2539_CR52) 2018; 392
JP Dwyer (2539_CR17) 2012; 2
A Rawshani (2539_CR9) 2018; 379
A Chagnac (2539_CR14) 2008; 23
HJL Heerspink (2539_CR43) 2020; 383
B Zinman (2539_CR45) 2014; 13
WW Williams (2539_CR25) 2021; 385
DS Hsia (2539_CR40) 2017; 24
Kidney Disease Improving Global Outcomes Blood Pressure Work Group (2539_CR34) 2021; 99
HC Gerstein (2539_CR42) 2019; 394
CP Cannon (2539_CR48) 2020; 383
JFE Mann (2539_CR51) 2017; 377
A-S Bargnoux (2539_CR29) 2017; 63
C Cappelli (2539_CR13) 2020; 1866
American Diabetes Association (2539_CR21) 2020; 43
DC Chen (2539_CR28) 2022; 5
F Ismail-Beigi (2539_CR70) 2010; 376
K Matsushita (2539_CR31) 2010; 375
R Agarwal (2539_CR57) 2022; 43
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2539_CR22) 2013; 3
UK Prospective Diabetes Study Group (2539_CR63) 1998; 352
TWC Tervaert (2539_CR19) 2010; 21
American Diabetes Association (2539_CR35) 2020; 44
SM Doshi (2539_CR33) 2017; 12
G Xu (2539_CR2) 2018; 362
SH Ballew (2539_CR20) 2018; 38
JL Górriz (2539_CR8) 2020; 9
W Lv (2539_CR39) 2020; 20
R Pichler (2539_CR12) 2017; 312
Kidney Disease Improving Global Outcomes Lipid Work Group (2539_CR36) 2013; 3
JJ Neumiller (2539_CR50) 2009; 49
M Packer (2539_CR49) 2020; 383
C Wanner (2539_CR44) 2016; 375
J Barrera-Chimal (2539_CR72) 2019; 96
BR Hemmelgarn (2539_CR30) 2010; 303
RZ Alicic (2539_CR55) 2021; 17
V Perkovic (2539_CR41) 2019; 380
M Diamant (2539_CR62) 2003; 63
B Pitt (2539_CR68) 2021; 385
References_xml – volume: 373
  start-page: 2247
  year: 2015
  ident: 2539_CR58
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1509225
– volume: 385
  start-page: 1804
  year: 2021
  ident: 2539_CR25
  publication-title: N Engl J Med
  doi: 10.1056/NEJMe2114918
– volume: 25
  start-page: 181
  year: 2018
  ident: 2539_CR10
  publication-title: Adv Chronic Kidney Dis
  doi: 10.1053/j.ackd.2017.12.002
– volume: 1866
  start-page: 165796
  year: 2020
  ident: 2539_CR13
  publication-title: Biochim Biophys Acta Mol basis Dis
  doi: 10.1016/j.bbadis.2020.165796
– volume: 98
  start-page: S1
  year: 2020
  ident: 2539_CR27
  publication-title: Kidney Int
  doi: 10.1016/j.kint.2020.06.019
– volume: 375
  start-page: 323
  year: 2016
  ident: 2539_CR44
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1515920
– volume: 30
  start-page: 250
  year: 2019
  ident: 2539_CR6
  publication-title: Mol Metab
  doi: 10.1016/j.molmet.2019.10.005
– volume: 376
  start-page: 419
  year: 2010
  ident: 2539_CR70
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(10)60576-4
– volume: 63
  start-page: 833
  year: 2017
  ident: 2539_CR29
  publication-title: Clin Chem
  doi: 10.1373/clinchem.2016.264325
– volume: 23
  start-page: 3946
  year: 2008
  ident: 2539_CR14
  publication-title: Nephrol Dial Transplant
  doi: 10.1093/ndt/gfn379
– volume: 303
  start-page: 423
  year: 2010
  ident: 2539_CR30
  publication-title: JAMA.
  doi: 10.1001/jama.2010.39
– volume: 12
  start-page: 73
  year: 2016
  ident: 2539_CR4
  publication-title: Nat Rev Nephrol
  doi: 10.1038/nrneph.2015.173
– volume: 360
  start-page: 129
  year: 2009
  ident: 2539_CR69
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0808431
– volume: 312
  start-page: F716
  year: 2017
  ident: 2539_CR12
  publication-title: Am J Physiol Ren Physiol
  doi: 10.1152/ajprenal.00314.2016
– volume: 18
  start-page: 1353
  year: 2007
  ident: 2539_CR23
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.2006080872
– volume: 383
  start-page: 1425
  year: 2020
  ident: 2539_CR48
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2004967
– volume-title: A research study to find out how semaglutide works in the kidneys compared to placebo, in people with type 2 diabetes and chronic kidney disease (the REMODEL trial)
  year: 2022
  ident: 2539_CR66
– volume: 384
  start-page: 1437
  year: 2021
  ident: 2539_CR15
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra1808786
– volume: 383
  start-page: 1413
  year: 2020
  ident: 2539_CR49
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2022190
– volume: 317
  start-page: 703
  year: 1998
  ident: 2539_CR37
  publication-title: BMJ
  doi: 10.1136/bmj.317.7160.703
– volume: 17
  start-page: 227
  year: 2021
  ident: 2539_CR55
  publication-title: Nat Rev Nephrol
  doi: 10.1038/s41581-020-00367-2
– volume: 71
  start-page: 599
  issue: 4
  year: 2018
  ident: 2539_CR73
  publication-title: Hypertension.
  doi: 10.1161/HYPERTENSIONAHA.117.10360
– ident: 2539_CR1
– volume: 26
  start-page: 144
  year: 2021
  ident: 2539_CR18
  publication-title: Eur J Med Res
  doi: 10.1186/s40001-021-00612-9
– volume: 79
  start-page: 268
  year: 2022
  ident: 2539_CR24
  publication-title: Am J Kidney Dis
  doi: 10.1053/j.ajkd.2021.08.003
– volume: 127
  start-page: 154937
  year: 2022
  ident: 2539_CR71
  publication-title: Metabolism.
  doi: 10.1016/j.metabol.2021.154937
– volume: 44
  start-page: S125
  year: 2020
  ident: 2539_CR35
  publication-title: Diabetes Care
  doi: 10.2337/dc21-S010
– volume: 385
  start-page: 2252
  year: 2021
  ident: 2539_CR68
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2110956
– volume: 5
  start-page: e2148940
  year: 2022
  ident: 2539_CR28
  publication-title: JAMA Netw Open
  doi: 10.1001/jamanetworkopen.2021.48940
– volume: 385
  start-page: 1737
  year: 2021
  ident: 2539_CR26
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2102953
– volume: 12
  start-page: 1366
  year: 2017
  ident: 2539_CR33
  publication-title: Clin J Am Soc Nephrol
  doi: 10.2215/CJN.11111016
– volume: 362
  start-page: k1497
  year: 2018
  ident: 2539_CR2
  publication-title: BMJ.
  doi: 10.1136/bmj.k1497
– volume: 2
  start-page: 1
  year: 2012
  ident: 2539_CR17
  publication-title: Cardiorenal Med
  doi: 10.1159/000333249
– volume: 375
  start-page: 1834
  year: 2016
  ident: 2539_CR53
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1607141
– volume: 99
  start-page: S1
  year: 2021
  ident: 2539_CR34
  publication-title: Kidney Int
  doi: 10.1016/j.kint.2020.11.003
– volume: 12
  start-page: 2032
  year: 2017
  ident: 2539_CR11
  publication-title: Clin J Am Soc Nephrol
  doi: 10.2215/CJN.11491116
– volume: 377
  start-page: 839
  year: 2017
  ident: 2539_CR51
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1616011
– volume: 379
  start-page: 633
  year: 2018
  ident: 2539_CR9
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1800256
– volume: 316
  start-page: 602
  issue: 6
  year: 2016
  ident: 2539_CR59
  publication-title: JAMA.
  doi: 10.1001/jama.2016.10924
– volume: 42
  start-page: 152
  issue: 2
  year: 2021
  ident: 2539_CR74
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehaa736
– volume: 24
  start-page: 73
  year: 2017
  ident: 2539_CR40
  publication-title: Curr Opin Endocrinol Diabetes Obes
  doi: 10.1097/MED.0000000000000311
– volume: 21
  start-page: 556
  year: 2010
  ident: 2539_CR19
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.2010010010
– volume: 9
  start-page: 947
  year: 2020
  ident: 2539_CR8
  publication-title: J Clin Med
  doi: 10.3390/jcm9040947
– volume: 377
  start-page: 2099
  year: 2017
  ident: 2539_CR46
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1611925
– volume: 392
  start-page: 1519
  year: 2018
  ident: 2539_CR52
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(18)32261-X
– volume: 49
  start-page: S16
  issue: Suppl 1
  year: 2009
  ident: 2539_CR50
  publication-title: J Am Pharm Assoc (2003)
  doi: 10.1331/JAPhA.2009.09078
– ident: 2539_CR3
– volume: 20
  start-page: 37
  year: 2020
  ident: 2539_CR39
  publication-title: Curr Top Med Chem
  doi: 10.2174/1568026620666191224141617
– volume: 383
  start-page: 2219
  year: 2020
  ident: 2539_CR67
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2025845
– volume: 43
  start-page: 474
  year: 2022
  ident: 2539_CR57
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehab777
– volume: 385
  start-page: 896
  year: 2021
  ident: 2539_CR60
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2108269
– volume: 29
  start-page: 1802
  year: 2011
  ident: 2539_CR16
  publication-title: J Hypertens
  doi: 10.1097/HJH.0b013e3283495cd6
– volume: 380
  start-page: 2295
  year: 2019
  ident: 2539_CR41
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1811744
– volume: 383
  start-page: 1436
  year: 2020
  ident: 2539_CR43
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2024816
– volume-title: A Reseach Study to See How Semaglutide Works Compared to Placebo in People with Type 2 Diabetes and Chronic Kidney Disease (FLOW)
  year: 2022
  ident: 2539_CR65
– volume: 375
  start-page: 2073
  year: 2010
  ident: 2539_CR31
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(10)60674-5
– volume: 13
  start-page: 102
  year: 2014
  ident: 2539_CR45
  publication-title: Cardiovasc Diabetol
  doi: 10.1186/1475-2840-13-102
– volume: 3
  start-page: 1
  year: 2013
  ident: 2539_CR22
  publication-title: Kidney Int Suppl
  doi: 10.1038/kisup.2012.73
– volume: 43
  start-page: S66
  year: 2020
  ident: 2539_CR32
  publication-title: Diabetes Care
  doi: 10.2337/dc20-S006
– volume: 3
  start-page: 346
  year: 2021
  ident: 2539_CR7
  publication-title: J Diabetes Investig
  doi: 10.1111/jdi.13355
– volume: 90
  start-page: 8
  year: 2016
  ident: 2539_CR64
  publication-title: Kidney Int
  doi: 10.1016/j.kint.2016.05.002
– volume: 352
  start-page: 837
  year: 1998
  ident: 2539_CR63
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(98)07019-6
– volume: 5
  start-page: 49
  year: 2016
  ident: 2539_CR5
  publication-title: J Nephropharmacol
– volume: 38
  start-page: 208
  year: 2018
  ident: 2539_CR20
  publication-title: Semin Nephrol
  doi: 10.1016/j.semnephrol.2018.02.002
– volume: 15
  start-page: 569
  year: 2019
  ident: 2539_CR38
  publication-title: Nat Rev Endocrinol
  doi: 10.1038/s41574-019-0242-2
– volume: 23
  start-page: 479
  year: 2009
  ident: 2539_CR61
  publication-title: Best Pract Res Clin Endocrinol Metab
  doi: 10.1016/j.beem.2009.03.004
– volume: 96
  start-page: 302
  year: 2019
  ident: 2539_CR72
  publication-title: Kidney Int
  doi: 10.1016/j.kint.2019.02.030
– volume: 63
  start-page: 1373
  year: 2003
  ident: 2539_CR62
  publication-title: Drugs.
  doi: 10.2165/00003495-200363130-00004
– volume: 380
  start-page: 347
  year: 2018
  ident: 2539_CR47
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1812389
– volume: 3
  start-page: 259
  year: 2013
  ident: 2539_CR36
  publication-title: Kidney Int Suppl
  doi: 10.1038/kisup.2013.27
– volume: 43
  start-page: S135
  year: 2020
  ident: 2539_CR21
  publication-title: Diabetes Care
  doi: 10.2337/dc20-S011
– volume: 6
  start-page: 605
  year: 2018
  ident: 2539_CR56
  publication-title: Lancet Diabetes Endocrinol
  doi: 10.1016/S2213-8587(18)30104-9
– volume: 394
  start-page: 131
  year: 2019
  ident: 2539_CR42
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(19)31150-X
– volume: 29
  start-page: 145
  year: 2020
  ident: 2539_CR75
  publication-title: Curr Opin Nephrol Hypertens
  doi: 10.1097/MNH.0000000000000557
– volume: 18
  start-page: 138
  year: 2019
  ident: 2539_CR54
  publication-title: Cardiovasc Diabetol
  doi: 10.1186/s12933-019-0942-x
SSID ssj0025774
Score 2.5668237
SecondaryResourceType review_article
Snippet Background Diabetic kidney disease (DKD), the most common cause of kidney failure and end-stage kidney disease worldwide, will develop in almost half of all...
Diabetic kidney disease (DKD), the most common cause of kidney failure and end-stage kidney disease worldwide, will develop in almost half of all people with...
Abstract Background Diabetic kidney disease (DKD), the most common cause of kidney failure and end-stage kidney disease worldwide, will develop in almost half...
SourceID doaj
pubmedcentral
proquest
gale
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 1
SubjectTerms Blood pressure
Cardiovascular disease
Care and treatment
Cholesterol
Clinical outcomes
Clinical trials
Creatinine
Diabetes
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Diabetic kidney disease
Diabetic nephropathies
Diabetic nephropathy
Diagnosis
End-stage renal disease
Glomerular filtration rate
Glucose
Health services
Hemodialysis
Hypertension
Kidney diseases
Kidney protective agents
Kidneys
Mortality
Pathophysiology
Reagents
Renal failure
Review
Risk factors
Transplants & implants
Type 2 diabetes
SummonAdditionalLinks – databaseName: Directory of Open Access Journals - May need to register for free articles
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Pa9VAEB5KD6UX0VoxttotCB4k9GV_Jscq1lKopxZ6W7KbXXwoeaUv7-B_78xm82gU9NJDLtlZSGZndr5JZr4FeO8wiMmoVCmCiZigVG2JqJWXGK0xnsiovaLm5Otv-vJWXt2pu0dHfVFN2EgPPCruTGN2vgiat1FWMvBF7RGwUJaAu2oVjKPdF2PelEzlVEuh0NQiU-uzNUa1ioptOV5KNCWfhaHE1v_3nvxnneSjwHPxHJ5lxMjOxyd9ATuhP4C96_xP_CV8xX2KrYeJ8oENK7ZMXwoCm9oe2WozoGXhIEJUNn5uXXr2Y9n14RfL_2gO4fbiy83nyzIfj1B6LcxQ8rZDNOOMNkEYEV3dRdkh_lLcYXbJuReuNVzEWDWy442vTYjO604pEYicWLyC3X7Vh9fAgmm8bnjoQuxkzV3TqrYlYqroid_PFVBN2rI-c4fTERY_bcoham1HDVvUsE0atryAj9s59yNzxj-lP9EibCWJ9TrdQFuw2Rbs_2yhgBNaQju2kG59154bOoZLIlgs4EOSIO_FF_BtbkJANRAP1kzyeCaJXufnw5OZ2Oz1a8sNJpMCMZop4HQ7TDOpkq0Pq02SEZgkIooqwMzMa_bu85F--T0xfxM7n6j1m6dQ1hHsc3IIqs5ZHMPu8LAJbxFgDe5d8qXfgOMeLw
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZKkRCXikcRgUKNVIlDFbXxMzmhgmirSuXUSnuz4hesQEnpZg_998w4zpaA1MNe4omyHns839jjbwg5sODERJSy5EFHCFCqtgTUykrw1uBPRFRO4uXky2_q_FpcLOQib7itclrltCamhdr3DvfIj5gGoM7B_-lPN79LrBqFp6u5hMYj8hipy3BW68V9wCUB20wXZWp1tALfVmHKLYOf5E3JZs4ocfb_vzL_my35l_s5fUZ2Mm6kJ-NAPydboXtBnlzmk_GX5AxWK7oaJuIHOvR0mfYLAp0uP9J-PUBfoRGAKh03XZeO_lz6LtzRfFKzS65Pv159OS9zkYTSKa6HkrUeMI3VSgeuebS1j8IDCpPMQozJmOO21YzHWDXCs8bVOkTrlJeSB6Qo5q_Idtd34TWhQTdONSz4EL2omW1a2bZITxUdsvzZglSTtozLDOJYyOKXSZFErcyoYQMaNknDhhXkcPPOzcif8aD0ZxyEjSRyX6cH_e13k03JKAYQNyjWRlGJwI5rB8OMcSP42Spo-Jv7OIRmvEi6sWBzorEYlwDIWJCPSQJtGDrg2nwVAdSAbFgzyb2ZJNiemzdP08Rk21-Z-5lakA-bZnwT89m60K-TDIdQEbBUQfRses36Pm_plj8S_zdy9PFavXn442_JU4ZTHbNvjvfI9nC7Du8AQA32fbKSP6x7F4U
  priority: 102
  providerName: ProQuest
Title New strategies to improve clinical outcomes for diabetic kidney disease
URI https://www.proquest.com/docview/2725937417
https://www.proquest.com/docview/2723487613
https://pubmed.ncbi.nlm.nih.gov/PMC9548386
https://doaj.org/article/62020e62af414e208c77428994711e7b
Volume 20
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3da9RAEB9qC-KL-InReq4g-CDRZnezmzyI9KS1CFekeHD4siSb3XpYkvYuB_a_d2aTHEaLPtw93E6O7OzMzm_24zcAr0oMYtKnaSyc9pigJEWMqJXHGK0xnkivbEqXk2en6mQuPy_SxQ4M5Y56Ba5vTO2ontR8dfH259X1B3T498HhM_VujTEroaO0HD-pyGOckvcwMmmqaDCT210FtM7AyowgPIk1xsHhEs2N_zEKVIHP_-9Z-8-TlL-FpuN7cLfHlOywM4L7sOPqB3B71u-aP4RPOJOxdTuQQrC2YcuwluDYcDGSNZsWbQ8bEcSybkF2admPZVW7a9bv4jyC-fHR148ncV9AIbZK6DbmRYV4p9RKO6GFL7PKywoRWspLzD85t6IsNBfeJ7mseG4z7XxpVZWmwhF9sXgMu3VTuyfAnM6tyrmrnK9kxsu8SIuCqKu8JQbAMoJk0JaxPbs4Fbm4MCHLyJTpNGxQwyZo2PAI3myfuey4Nf4pPaVB2EoSL3b4oVmdm97NjOIIf53ihZeJdPwgszjklFNiDE6cxtd8QUNoukumW-82h5oKdUmEkxG8DhJkcdgBW_TXFFANxJQ1ktwfSaJf2nHzYCZmMGvDNaabAu1PR_By20xP0lm32jWbICMwjUScFYEemdeo7-OWevk9cIMTf5_I1NP_9vMZ3OFk7XQ452AfdtvVxj1HfNWWE7ilF3oCe9Oj0y9nk7BKMQmOhN9n02-_AKLbIhk
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIgEXxFMECjUSiAOKurFjOzkgVB5lS7s9tdLeTOLYsAIlpZsV6p_iNzLjJFsCUm897CWeZJPxeOYbex4AL0o0YqmXMhZOe3RQkiJG1MpjtNZoT1KvrKTk5NmRmp6kn-dyvgG_h1wYCqscdGJQ1FVjaY98h2sE6gLtn357-jOmrlF0ujq00OjE4sCd_0KXbflm_wPO70vO9z4ev5_GfVeB2Cqh25gXFYKAUivthBa-zCqfVghbJC_RKePcirLQXHiP7n3Fc5tp50urKimFo5q-Ap97Da6j4Z2Qs6fnFw6eRCw1JOZkameJtjShEF-OPynymI-MX-gR8L8l-Dc68y9zt3cHbvc4le12gnUXNlx9D27M-pP4-_AJtSNbtkOhCdY2bBH2Jxwbki1Zs2qRtziIwJh1m7wLy74vqtqds_5k6AGcXAn7HsJm3dTuETCnc6ty7irnqzTjZV7IoqByWN5SVcEygmTglrF9xXJqnPHDBM8lU6bjsEEOm8BhwyN4vb7ntKvXcSn1O5qENSXV2g4XmrOvpl-6RnGE1E7xwqdJ6vgkszjN5KeiXU-cxtfcpik0XeLqWmOYXU3Nv1KEqBG8ChSkM_ADbNGnPiAbqPrWiHJrRIlr3Y6HBzExva5ZmouVEcHz9TDdSfFztWtWgUaga4rYLQI9Eq_Rt49H6sW3UG-cagKKTD2-_M-34eb0eHZoDvePDp7ALU5iT5E_ky3YbM9W7imCt7Z8FlYMgy9XvUT_AA56U9I
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=New+strategies+to+improve+clinical+outcomes+for+diabetic+kidney+disease&rft.jtitle=BMC+medicine&rft.au=Papanas%2C+Nikolaos&rft.au=Streckbein%2C+Marina&rft.au=Tuttle%2C+Katherine+R&rft.au=Mathieu%2C+Chantal&rft.date=2022-10-10&rft.pub=BioMed+Central+Ltd&rft.issn=1741-7015&rft.eissn=1741-7015&rft.volume=20&rft.issue=1&rft_id=info:doi/10.1186%2Fs12916-022-02539-2&rft.externalDBID=n%2Fa&rft.externalDocID=A721724545
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1741-7015&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1741-7015&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1741-7015&client=summon